Cargando…

Tumor homing peptide modified liposomes of capecitabine for improved apoptotic activity and HER2 targeted therapy in breast cancer: in vitro studies

In the present study, we have formulated a liposomal formulation of cytotoxic agent capecitabine (CAP) to overcome its bioavailability issues. Then we have surface modified CAP loaded liposomes (CAP-LPs) with a tumour homing peptide (THP-CAP-LPs) to achieve site specific delivery to breast cancer ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Mantosh Kumar, Pindiprolu, Sai Kiran S. S., Reddy Sanapalli, Bharat Kumar, Yele, Vidyasrilekha, Ganesh, G. N. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society of Chemistry 2019
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070003/ https://www.ncbi.nlm.nih.gov/pubmed/35528678 http://dx.doi.org/10.1039/c9ra04814f

Ejemplares similares

Imidazoles and benzimidazoles as putative inhibitors of SARS-CoV-2 B.1.1.7 (Alpha) and P.1 (Gamma) variant spike glycoproteins: A computational approach
por: Yele, Vidyasrilekha., et al.
Publicado: (2021)

Benzohydrazide and Phenylacetamide Scaffolds: New Putative ParE Inhibitors
por: Yele, Vidyasrilekha, et al.
Publicado: (2021)

Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study
por: Patel, Simran, et al.
Publicado: (2023)

Ligand-based pharmacophore modeling and molecular dynamic simulation approaches to identify putative MMP-9 inhibitors
por: Sanapalli, Bharat Kumar Reddy, et al.
Publicado: (2021)

Synthetic Imidazopyridine-Based Derivatives as Potential Inhibitors against Multi-Drug Resistant Bacterial Infections: A Review
por: Sanapalli, Bharat Kumar Reddy, et al.
Publicado: (2022)

Filamentous temperature sensitive mutant Z: a putative target to combat antibacterial resistance
por: Kifayat, Sumaiya, et al.
Publicado: (2023)

Polysorbate-80 surface modified nano-stearylamine BQCA conjugate for the management of Alzheimer's disease
por: Chintamaneni, Pavan Kumar, et al.
Publicado: (2021)

Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19
por: Pindiprolu, Sai Kiran S.S., et al.
Publicado: (2020)

Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria
por: Gujjari, Lohitha, et al.
Publicado: (2022)

Smart niosomes of temozolomide for enhancement of brain targeting
por: De, Anindita, et al.
Publicado: (2018)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo
por: Wang, Chao, et al.
Publicado: (2015)

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
por: Saura, Cristina, et al.
Publicado: (2020)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells
por: Ringhieri, Paola, et al.
Publicado: (2017)

A case of capecitabine-induced dermatomyositis
por: Saraswat, Neerja, et al.
Publicado: (2018)

Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent
por: Pindiprolu, Sai Kiran S.S., et al.
Publicado: (2020)

Cell-Penetrating Peptide and Transferrin Co-Modified Liposomes for Targeted Therapy of Glioma
por: Wang, Xi, et al.
Publicado: (2019)

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
por: Wu, Yue, et al.
Publicado: (2022)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
por: Harder, J, et al.
Publicado: (2012)

A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients
por: Yuan, Yuan, et al.
Publicado: (2021)

Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide
por: Lin, Congcong, et al.
Publicado: (2018)

An FGFR1-Binding Peptide Modified Liposome for siRNA Delivery in Lung Cancer
por: Dong, Zhipeng, et al.
Publicado: (2022)

Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
por: Bao, Yuwen, et al.
Publicado: (2022)

Novel dermacozine-1-carboxamides as promising anticancer agents with tubulin polymerization inhibitory activity
por: Ghanta, Venkata Rao, et al.
Publicado: (2019)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021)

Novel antimicrobial peptide–modified azithromycin-loaded liposomes against methicillin-resistant Staphylococcus aureus
por: Liu, Xiaowei, et al.
Publicado: (2016)

Attention-based bidirectional-long short-term memory for abnormal human activity detection
por: Kumar, Manoj, et al.
Publicado: (2023)

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2018)

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months’ Remission with Lapatinib plus Capecitabine
por: Mailliez, Audrey, et al.
Publicado: (2014)

Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer
por: Lee, Jieun, et al.
Publicado: (2017)

Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
por: Gui, Xinyu, et al.
Publicado: (2020)

Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis
por: Hu, Yiyi, et al.
Publicado: (2023)

Capecitabine-induced Leukoencephalopathy
por: Yoshimura, Kenji, et al.
Publicado: (2018)

Capecitabine-Induced Enterocolitis
por: Khan, Muzammil, et al.
Publicado: (2022)

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct
por: Roth, A, et al.
Publicado: (2005)

Optimization of a Method to Prepare Liposomes Containing HER2/Neu- Derived Peptide as a Vaccine Delivery System for Breast Cancer
por: Shariat, Sheyda, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rg3r15s6452j5obcemebpfdtto